Sanofi Loses Two Patents for Blockbuster Insulin Drug

Drug Industry Daily
A A
The PTO’s Patent Trial and Appeal Board invalidated two patents for Sanofi’s cash cow Lantus (insulin glargine) siding with Mylan in its inter partes review proceedings.

To View This Article:

Login

Subscribe To Drug Industry Daily